Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SYK | P43405 | 8/20 | 0.50 |
| ▸ | STAT6 | P42226 | 4/20 | 0.44 |
| ▸ | RPS6KB1 | P23443 | 2/20 | 0.39 |
| ▸ | SIRT2 | Q8IXJ6 | 2/20 | 0.39 |
| ▸ | PLK2 | Q9NYY3 | 1/20 | 0.39 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.39 |
| ▸ | JAK2 | O60674 | 1/20 | 0.38 |
| ▸ | JAK1 | P23458 | 1/20 | 0.38 |
| ▸ | JAK3 | P52333 | 1/20 | 0.38 |
| ▸ | PARP1 | P09874 | 1/20 | 0.38 |
| ▸ | AKT1 | P31749 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17005753 | 0.83 | SYK (0.54) | SYKSTAT6SIRT2KCNH2 | |
| SCHEMBL764210 | 0.74 | SYK (0.66) | SYK | |
| SCHEMBL763440 | 0.72 | SYK (0.60) | SYKKCNH2 | |
| SCHEMBL18351951 | 0.67 | SYK (0.48) | SYKPLK2JAK2JAK3PARP1 | |
| SCHEMBL1354204 | 0.67 | SYK (1.00) | SYK | |
| SCHEMBL1354205 | 0.67 | SYK (1.00) | SYK | |
| SCHEMBL31156717 | 0.67 | RET (0.51) | SYKPLK2JAK2JAK3 | |
| SCHEMBL1354086 | 0.66 | SYK (0.79) | SYK | |
| SCHEMBL12520368 | 0.66 | HTR1A (0.46) | — | |
| SCHEMBL1353927 | 0.66 | SYK (0.76) | SYKKCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9533989-B2 | Substituted pyrimidine-5-carboxamides as spleen tyrosine kinase inhibitors | Ziarco Pharma Ltd. (GB) | 2017-01-03 | — | — | US | disclosed |
| US-20150232470-A1 | 2-(-Aminocyclohexyl)Amino-Pyrimidine-5-Carboxamides as Spleen Tyrosine Kinasei(SYK) Inhibitors | PFIZER LIMITED (GB) | 2015-08-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150232470-A1 | 2-(-Aminocyclohexyl)Amino-Pyrimidine-5-Carboxamides as Spleen Tyrosine Kinasei(SYK) Inhibitors | SYK, BTK, LCK | SYK 1/4885STAT6 78/4885RPS6KB1 1027/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.